# Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

> **NCT02427581** · PHASE1 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Triple Negative Breast Cancer
- Triple Negative Breast Neoplasms
- Triple-Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** Personalized synthetic long peptide vaccine (Poly ICLC)
- **DRUG:** Poly ICLC

## Key facts

- **NCT ID:** NCT02427581
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-09-29
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Drugs not available
- **Last updated:** 2022-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02427581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02427581, "Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02427581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*